VAG
DFTX

VisionPoint Advisory Group’s Definium Therapeutics DFTX Stock Holding History

VisionPoint Advisory Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$50 – 820
2023
Q3 		$50 Buy
+16
New +$66 ﹤0.01% 676
2022
Q3 		– Sell
-833
Closed -$8K – 101
2022
Q2 		$8K Buy
833
+166
+25% +$2.1K ﹤0.01% 100
2022
Q1 		$7K Buy
+667
New +$11.6K ﹤0.01% 90

Other funds holding DFTX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VisionPoint Advisory Group's DFTX Position: Q4 2023 in Review

VisionPoint Advisory Group sold out of Definium Therapeutics (DFTX) in Q4 2023, closing a stake of 16 shares — an estimated $50 sold.

VisionPoint Advisory Group first reported a position in DFTX in Q1 2022 and held it in 3 quarters. The position peaked at $8K in Q2 2022. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2023.

  • VisionPoint Advisory Group reported no remaining Definium Therapeutics position as of Q4 2023 after selling out during the quarter.
  • VisionPoint Advisory Group sold 16 Definium Therapeutics shares in Q4 2023, an estimated $50.
  • VisionPoint Advisory Group first reported a position in Definium Therapeutics in Q1 2022 and held it in 3 quarters.
  • VisionPoint Advisory Group's Definium Therapeutics position peaked at $8K in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2023.

Based on VisionPoint Advisory Group's 13F filing for Q4 2023, filed 7 Feb 2024.